ALT Stock Risk & Deep Value Analysis
Altimmune Inc
Healthcare • Biotechnology
DVR Score
out of 10
The Bottom Line on ALT
We analyzed Altimmune Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran ALT through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Here's what we found.
📈ALT Performance Overview3yr weekly
Unlock ALT Performance Chart
See 3 years of price history, quarterly revenue trends, and DVR score changes
Weekly adjusted close · Quarterly revenue & EPS · DVR score history
ALT Stock Risk Analysis
Overall Risk
Aggressive
Financial Risk
Medium
Market Risk
Medium
About Altimmune Inc (ALT)
Sector
Healthcare
Industry
Biotechnology
Market Cap Category
small
Market Cap
$428.29M
ALT Deep Value Analysis
ALT Red Flags & Warning Signs
Premium- ⚠
Phase 3 trial delays or unexpected adverse events
- ⚠
Negative or non-differentiated RECLAIM Phase 2 data
- ⚠
Failure to secure a strategic partnership for Pemvidutide
- ⚠
Increased competitive pressure or emergence of superior therapies
Unlock ALT Red Flags & Risk Warnings
Premium members see every risk event we found.
Unlock the full report
Create a free account to see the DVR score, risk flags, and AI analysis.
Unlock everything for $47/yr
$79/yrSave 41%
- ✓ Catalysts, bull case, moat & red flags
- ✓ Unlimited stock analyses + alerts
- ✓ Full database, search & portfolio (50 stocks)
7-day money back · Cancel anytime
ALT Financial Health Metrics
Market Cap
$428.29M
P/E Ratio
-3.50
Profit Margin
-214860.98%
Debt-to-Equity
0.16
Dividend Yield
0.00%
Beta (Volatility)
0.13
Earnings Per Share
$-0.27
ALT Competitive Moat Analysis
PremiumMoat Rating
Narrow
Moat Trend
Expanding
Moat Sources
2 Identified
The moat is primarily driven by intellectual property protection and the significant regulatory advantage of Breakthrough Therapy Designation, which can accelerate market entry and create a first-mover advantage for this specific mechanism in MASH. Its durability hinges on successful clinical outcomes and effective commercialization.
ALT Competitive Moat Analysis
Premium unlocks moat rating, sources & durability.
ALT Catalysts & Growth Drivers
Near-Term (0-6 months)
- •Q1 2026 Earnings (Estimated early May 2026)
- •Phase 3 MASH trial initiation (Planned 2026)
- •Topline data from RECLAIM Phase 2 trial (3Q 2026)
Medium-Term (6-18 months)
- •Strategic partnership announcement for Pemvidutide
- •Updates on MASH Phase 3 trial enrollment progress
- •Clinical trial updates for obesity program
Long-Term (18+ months)
- •Successful completion of MASH Phase 3 trials and data release
- •Regulatory submission and approval of Pemvidutide in MASH and/or obesity
- •Commercial launch and market penetration of Pemvidutide
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
ALT Bull Case: What Could Go Right
- ✓
Announcement of a strategic partnership for Pemvidutide
- ✓
Positive Phase 3 MASH clinical trial updates or interim data
- ✓
Cash burn rate relative to cash on hand and future funding needs
Bull Case Analysis
See what could go right with Premium
Never miss a move on ALT
Create a free account to set price alerts and get notified on Telegram when ALT hits your targets.
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential.
FAQ
What is the DVR Score for Altimmune Inc (ALT)?
As of March 23, 2026, Altimmune Inc has a DVR Score of 8.6 out of 10, placing it in the "Hidden Gem" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the market capitalization of Altimmune Inc?
Altimmune Inc's market capitalization is approximately $428.3M. The company operates in the Healthcare sector within the Biotechnology industry.
What ticker symbol does Altimmune Inc use?
ALT is the ticker symbol for Altimmune Inc. The company trades on the NGM.
What is the risk level for ALT stock?
Our analysis rates Altimmune Inc's overall risk as Aggressive. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
What is the P/E ratio of ALT?
Altimmune Inc currently has a price-to-earnings (P/E) ratio of -3.5. This is below the market average, which could indicate the stock is undervalued or facing headwinds.
Is Altimmune Inc's revenue growing?
Altimmune Inc has reported revenue growth of 0.0%. Revenue has been declining, which warrants closer examination.
Is ALT stock profitable?
Altimmune Inc has a profit margin of -214861.0%. The company is currently unprofitable.
How often is the ALT DVR analysis updated?
Our AI-powered analysis of Altimmune Inc is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on March 23, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research and consult with a qualified financial advisor.